tenofovir
Hepatitis B Virus Infection
Ruijin HospitalSmall moleculePhase 4 / ApprovedDormant
BB
71/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 95/ 100
Competitive context
22 Active assets in the Hepatitis B Virus Infection cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Entecavir Sun Yat-sen University | Phase 4 | BBB |
Lamivudine Fudan University | Phase 4 | BBB |
TENOFOVIR BIS(ISOPROPYLOXYCARBONYLOXYMETHYL) ESTER West China Hospital | Phase 4 | BB |
Hepatitis B Virus Vaccine Eunice Dube | Phase 4 | BB |
Hep-V Vax University of Oxford | Phase 4 | BB |
View all 42 →
Same molecule, other indications
tenofovir is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →